Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer

Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer

Among ovarian cancer patients with <i>BRCA</i> mutation or homologous recombination deficiency (HRD), the efficacy of Poly-ADP-ribose polymerase (PARP) inhibitors such as olaparib, niraparib, veliparib, and rucaparib has been proven in a number of clinical trials. <i>BRCA</i>...

Full description

Bibliographic Details
Main Authors: E Sun Paik, Ha Kyun Chang, Sanghoon Lee
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cancers
Subjects:
PARP inhibitors
ovarian cancer
<i>BRCA</i>
HRD
prevalence
Online Access:https://www.mdpi.com/2072-6694/15/12/3095

Internet

https://www.mdpi.com/2072-6694/15/12/3095

Similar Items